https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54877 Wed 20 Mar 2024 13:18:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38205 2 = 0.0%; p=0.5). Conclusion: Although the CVS is a clinically relevant and viable sign, further work is needed to integrate this into the existing diagnostic criteria. As manual determination is a time-consuming process, the development of automated methods will be beneficial. With improvements in computational imaging techniques, the CVS will have an important role in the diagnosis and differentiation of MS.]]> Wed 11 Aug 2021 12:11:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4487 Wed 11 Apr 2018 15:32:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34629 Wed 09 Feb 2022 15:57:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45616 Wed 02 Nov 2022 14:34:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32621 -6) and followed by variants in GAPVD1 (GTPase activating protein and VPS9 domains 1; combined P-value 5.83 × 10^-5) and near ZNF697 (combined P-value 8.15 × 10^-5).]]> Tue 26 Jun 2018 14:58:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54315 Tue 20 Feb 2024 14:35:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51798 Tue 19 Sep 2023 08:56:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13657 s) was similar across all sites. The familial recurrence risk of MS in Australia is lower than in previously reported studies. This is directly related to the lower population prevalence of MS. The overall genetic susceptibility in Australia as measured by the λ_s is similar to the northern hemisphere, suggesting that the difference in population risk is explained largely by environmental factors rather than by genetic admixture.]]> Sat 24 Mar 2018 08:25:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12486 Sat 24 Mar 2018 08:15:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10938 Sat 24 Mar 2018 08:13:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10441 Sat 24 Mar 2018 08:13:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10808 Sat 24 Mar 2018 08:11:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18773 trend= 0.086). Conclusion: Seasonal fluctuation of MS births as found in this worldwide cohort of patients with MS did not correlate with variation in seasonal fluctuation of UV-light. Most likely, it results from a complex interplay between fluctuation of sunlight, behavioural factors, other environmental factors and (epi)genetic factors.]]> Sat 24 Mar 2018 07:51:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29000 Sat 24 Mar 2018 07:41:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28462 p = 0.02). Furthermore, the outcome of patients negative for CSF-specific OCB was significantly better in comparison to the OCB positive patients, as assessed by Expanded Disability Status Scale change (p < 0.001). Conclusions: The results of this study indicate that latitude could explain some of the inconsistencies in OCB status reported in different populations. The study confirms that OCB positivity in MS is associated with a worse long-term prognosis.]]> Sat 24 Mar 2018 07:39:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27967 Sat 24 Mar 2018 07:38:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29982 Sat 24 Mar 2018 07:37:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30017 Sat 24 Mar 2018 07:28:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42843 n = 195; untreated n = 338). Median on-study pairwise-censored follow-up was 3.4 years (quartiles 1.2–5.5). No difference in the hazard of experiencing 3-month confirmed EDSS progression events was observed between the groups [hazard ratio (HR), 1.0; 95% confidence interval (CI), 0.6–1.7, P = 0.87]. We did not find significant differences in the hazards of confirmed EDSS improvement (HR, 1.0; 95% CI, 0.6–1.6, P = 0.91) or reaching a confirmed EDSS step ≥7 (HR, 1.1; 95% CI, 0.7–1.6, P = 0.69). Conclusion: Our pooled analysis of disease-modifying agents suggests that these therapies have no substantial effect on short- to medium-term disability outcomes in PPMS.]]> Mon 05 Sep 2022 14:44:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51498 Fri 08 Sep 2023 11:55:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54685 Fri 08 Mar 2024 11:52:11 AEDT ]]>